GLP-1 Overdose: What the Reported Cases Actually Show

“Overdose” is the wrong mental model for what actually happens with GLP-1 medications, and the right one is less dramatic but more useful: the typical case is not someone taking a handful of pills, it is someone who took a weekly drug daily, or drew the wrong number on a syringe.

There is now national data on how often that happens and how it turns out.

If you think you have taken too much, contact Poison Control at 1-800-222-1222 in the US, or seek medical care. This page describes what the published data reports; it is not a substitute for that call.

How often does it happen?

A 2026 analysis in the Journal of Medical Toxicology pulled every human GLP-1 receptor agonist exposure reported to the National Poison Data System from 2012 through 2023 — 10,033 in total, split at semaglutide’s July 2021 obesity approval.

	Before approval	After approval
Exposures reported	3,113	6,920
Semaglutide share	—	64.2%
Managed in or referred to a health care facility	23.0%	33.5%

The rise in referrals is statistically solid: a relative risk of 1.46 (95% CI 1.36–1.57, p < 0.001), which in absolute terms is roughly one in four becoming one in three. Segmented modelling found semaglutide exposures increasing an additional 9.9% per quarter after approval.

The exposed population also shifted younger and more female — which is what you would expect as prescribing moved from type 2 diabetes toward weight management.

How bad is it, usually?

Here the data is reassuring without being permission to be careless.

The national analysis concluded that most cases were “unintentional therapeutic errors with mild gastrointestinal symptoms,” and a separate single-centre study reached the same verdict in its title: exposures are increasingly common and generally associated with mild symptoms.

“Mild,” in this context, means the symptoms are the familiar GLP-1 ones — nausea, vomiting, abdominal pain — rather than something new and dangerous. It does not mean brief. In the published case series of compounded semaglutide errors, all three patients had nausea, vomiting, and abdominal pain, with most symptoms lasting for days. One also reported headache, anorexia, weakness, and fatigue.

The generic version of this story is that a GLP-1 overdose produces a much larger dose of the side effects the drug already causes, for much longer, with no way to switch it off. The drug’s long half-life is the reason — the same property that makes weekly dosing possible makes a mistake persist.

That half-life logic is covered in why engineered GLP-1 drugs last a week, and the ordinary side-effect profile in GLP-1 side effects: what the trials report.

What causes the errors?

Three patterns account for most of what gets reported.

Weekly taken as daily. Semaglutide and tirzepatide are once-weekly. Taken daily, a therapeutic dose becomes roughly a sevenfold one without anything looking obviously wrong at the moment of injection.

Skipping titration. Starting at a maintenance dose rather than the lowest step. The escalation schedule exists specifically to manage gastrointestinal tolerability, which is why skipping it produces exactly the symptoms it was designed to prevent — see GLP-1 dosing and titration: why slow wins.

Vials and syringes instead of pens. This is the one that produces the tenfold errors. In the case series, two of three patients self-administered tenfold dosing errors. The authors are direct about the mechanism: vials of compounded semaglutide “do not use safety features provided by prefilled manufactured pens and allow for large overdoses,” and syringes not intended for semaglutide create confusion between millilitres, insulin units, and milligrams. One patient reported dosing in millilitres and units rather than milligrams. One received a vial and syringes with no pharmacist counselling at all.

That unit confusion is the same failure mode covered in peptide dosing errors: how a decimal ruins a dose, and it is a large part of why the compounded supply carries risks the approved pens do not — compounded semaglutide: the risks and realities.

Frequently asked questions

Can you overdose on Ozempic or Wegovy?

Yes, and it is usually accidental. In the reported national data most exposures were therapeutic errors rather than intentional misuse, and most produced mild gastrointestinal symptoms — though a third of post-approval cases were managed in or referred to a health care facility.

What happens if you take too much semaglutide?

The published cases describe amplified versions of the drug’s normal effects: nausea, vomiting, and abdominal pain, frequently lasting days. Hypoglycemia is a greater concern for people also taking insulin or a sulfonylurea, which is a question for a clinician rather than an article.

Is there an antidote for a GLP-1 overdose?

No reversal agent exists. Management in the reported cases was supportive — one patient “responded well to an antiemetic and intravenous fluids.” Because these drugs persist for days to a week, the exposure cannot simply be waited out over an afternoon.

What should I do if I took a double dose?

Contact Poison Control at 1-800-222-1222 in the US, or your prescriber. Both are equipped to weigh the actual dose, the drug, and your other medications, which is precisely the calculation that cannot be made from a web page.

Are compounded GLP-1s more dangerous?

The published case series points that way for administration error specifically (and the regulatory basis for compounded tirzepatide ended in early 2025 — what changed): vials drawn with a separate syringe lack the dose-limiting design of a prefilled pen, and that is the setting in which the tenfold errors occurred.

The takeaway

The reported picture is neither alarming nor trivial. Most GLP-1 overdoses are dosing mistakes that produce a bad few days of gastrointestinal symptoms and resolve with supportive care. But exposures rose sharply after the 2021 obesity approval, and the share ending up in front of a clinician rose with them, from 23.0% to 33.5%.

Almost all of it is preventable, and the preventable part is unglamorous: know whether your drug is weekly or daily, follow the titration schedule, and be very careful with any presentation that asks you to measure the dose yourself. If a mistake has already happened, the phone call is the right first step, not a search result.